Table 2.
Comparison of baseline characteristics and mortality rates in trials/subgroup analyses investigating DOAC or LMWH for the treatment of VTE in patients with cancer
| Parameter | Rivaroxaban versus VKA [15] | Dabigatran versus VKA [16] | Edoxaban versus VKA [17] | Tinzaparin versus VKA (CATCH) [12] | Edoxaban versus dalteparin (Hokusai VTE Cancer) [10] | Dalteparin versus VKA (CLOT) [3] | Rivaroxaban versus dalteparin (SELECT-D) [11] |
|---|---|---|---|---|---|---|---|
| Trial/subgroup analysis | |||||||
| Patients with cancer at baseline, na | 462 | 221 | 771 | 900 | 1046 | 676 | 406 |
| Patients with metastatic disease at baseline, n (%) | 101 (22) | 28 (13) | 46 (6) | 492 (55) | 554 (53) | 455 (67) | 236 (58) |
| Patients receiving antineoplastic therapy at baseline, n (%) | NR | NR | NR | 476 (53) | 757 (72) | 525 (78) | 282 (69) |
| ECOG PS = 2 | NR | NR | NR | 209 (23) | 247 (24) | 240 (36) | 95 (23) |
| Mortality rateb, n (%) | 74 (16)c | 32 (14)d | 80 (10)c | 288 (32)d | 267 (26)d | 266 (40)d | 104 (26)d |
DOAC direct oral anticoagulant, ECOG PS Eastern Cooperative Oncology Group performance status, LMWH low-molecular-weight-heparin, NR not reported, VKA vitamin K antagonist, VTE venous thromboembolism
aThe sum of solid and hematological malignancies
bCalculated as a percentage of the intention-to-treat population
c12-month mortality rate
d6-month mortality rate